Drugs / RP-G28
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03563846 | Mar → Apr 2018 | lactose intolerance | Ritter Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01113619 | Apr → Oct 2011 | lactose intolerance | Ritter Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02673749 | Feb → Oct 2016 | lactose intolerance | Ritter Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03597516 | Jun 2018 → Jul 2019 | lactose intolerance | Ritter Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP-G28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01113619 ↗ |
| Known as | galacto-oligosaccharide | “Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial.” PMID 24330605 ↗ Dec 2013 |
| Modality | Oligonucleotide (other) | “RP-G28 is novel galacto-oligosaccharide (GOS) being investigated to improve lactose digestion and the symptoms of lactose intolerance in affected patients.” PMID 24330605 ↗ Dec 2013 |
| Route | Oral | “Study drug taken orally” NCT02673749 ↗ |